作者
Robert P Baughman, Dominique Valeyre, Peter Korsten, Alexander G Mathioudakis, Wim A Wuyts, Athol Wells, Paola Rottoli, Hiliaro Nunes, Elyse E Lower, Marc A Judson, Dominique Israel-Biet, Jan C Grutters, Marjolein Drent, Daniel A Culver, Francesco Bonella, Katerina Antoniou, Filippo Martone, Bernd Quadder, Ginger Spitzer, Blin Nagavci, Thomy Tonia, David Rigau, Daniel R Ouellette
发表日期
2021/12/1
期刊
European Respiratory Journal
卷号
58
期号
6
出版商
European Respiratory Society
简介
Background
The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations.
Methods
A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight …
引用总数
学术搜索中的文章
RP Baughman, D Valeyre, P Korsten, AG Mathioudakis… - European Respiratory Journal, 2021